Suppr超能文献

术前放疗的最佳分割和直肠癌手术时机(斯德哥尔摩 III):一项多中心、随机、非盲、III 期、非劣效性试验。

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.

机构信息

Department of Molecular Medicine and Surgery, Karolinska Institutet and Centre of Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.

Department of Molecular Medicine and Surgery, Karolinska Institutet and Centre of Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Lancet Oncol. 2017 Mar;18(3):336-346. doi: 10.1016/S1470-2045(17)30086-4. Epub 2017 Feb 10.

Abstract

BACKGROUND

Radiotherapy reduces the risk of local recurrence in rectal cancer. However, the optimal radiotherapy fractionation and interval between radiotherapy and surgery is still under debate. We aimed to study recurrence in patients randomised between three different radiotherapy regimens with respect to fractionation and time to surgery.

METHODS

In this multicentre, randomised, non-blinded, phase 3, non-inferiority trial (Stockholm III), all patients with a biopsy-proven adenocarcinoma of the rectum, without signs of non-resectability or distant metastases, without severe cardiovascular comorbidity, and planned for an abdominal resection from 18 Swedish hospitals were eligible. Participants were randomly assigned with permuted blocks, stratified by participating centre, to receive either 5 × 5 Gy radiation dose with surgery within 1 week (short-course radiotherapy) or after 4-8 weeks (short-course radiotherapy with delay) or 25 × 2 Gy radiation dose with surgery after 4-8 weeks (long-course radiotherapy with delay). After a protocol amendment, randomisation could include all three treatments or just the two short-course radiotherapy treatments, per hospital preference. The primary endpoint was time to local recurrence calculated from the date of randomisation to the date of local recurrence. Comparisons between treatment groups were deemed non-inferior if the upper limit of a double-sided 90% CI for the hazard ratio (HR) did not exceed 1·7. Patients were analysed according to intention to treat for all endpoints. This study is registered with ClinicalTrials.gov, number NCT00904813.

FINDINGS

Between Oct 5, 1998, and Jan 31, 2013, 840 patients were recruited and randomised; 385 patients in the three-arm randomisation, of whom 129 patients were randomly assigned to short-course radiotherapy, 128 to short-course radiotherapy with delay, and 128 to long-course radiotherapy with delay, and 455 patients in the two-arm randomisation, of whom 228 were randomly assigned to short-course radiotherapy and 227 to short-course radiotherapy with delay. In patients with any local recurrence, median time from date of randomisation to local recurrence in the pooled short-course radiotherapy comparison was 33·4 months (range 18·2-62·2) in the short-course radiotherapy group and 19·3 months (8·5-39·5) in the short-course radiotherapy with delay group. Median time to local recurrence in the long-course radiotherapy with delay group was 33·3 months (range 17·8-114·3). Cumulative incidence of local recurrence in the whole trial was eight of 357 patients who received short-course radiotherapy, ten of 355 who received short-course radiotherapy with delay, and seven of 128 who received long-course radiotherapy (HR vs short-course radiotherapy: short-course radiotherapy with delay 1·44 [95% CI 0·41-5·11]; long-course radiotherapy with delay 2·24 [0·71-7·10]; p=0·48; both deemed non-inferior). Acute radiation-induced toxicity was recorded in one patient (<1%) of 357 after short-course radiotherapy, 23 (7%) of 355 after short-course radiotherapy with delay, and six (5%) of 128 patients after long-course radiotherapy with delay. Frequency of postoperative complications was similar between all arms when the three-arm randomisation was analysed (65 [50%] of 129 patients in the short-course radiotherapy group; 48 [38%] of 128 patients in the short-course radiotherapy with delay group; 50 [39%] of 128 patients in the long-course radiotherapy with delay group; odds ratio [OR] vs short-course radiotherapy: short-course radiotherapy with delay 0·59 [95% CI 0·36-0·97], long-course radiotherapy with delay 0·63 [0·38-1·04], p=0·075). However, in a pooled analysis of the two short-course radiotherapy regimens, the risk of postoperative complications was significantly lower after short-course radiotherapy with delay than after short-course radiotherapy (144 [53%] of 355 vs 188 [41%] of 357; OR 0·61 [95% CI 0·45-0·83] p=0·001).

INTERPRETATION

Delaying surgery after short-course radiotherapy gives similar oncological results compared with short-course radiotherapy with immediate surgery. Long-course radiotherapy with delay is similar to both short-course radiotherapy regimens, but prolongs the treatment time substantially. Although radiation-induced toxicity was seen after short-course radiotherapy with delay, postoperative complications were significantly reduced compared with short-course radiotherapy. Based on these findings, we suggest that short-course radiotherapy with delay to surgery is a useful alternative to conventional short-course radiotherapy with immediate surgery.

FUNDING

Swedish Research Council, Swedish Cancer Society, Stockholm Cancer Society, and the Regional Agreement on Medical Training and Clinical Research in Stockholm.

摘要

背景

放疗可降低直肠癌局部复发的风险。然而,放疗的最佳分割方式和放疗与手术之间的间隔时间仍存在争议。我们旨在研究三种不同放疗方案(分割方式和手术时间)的随机分组患者的复发情况。

方法

在这项多中心、随机、非盲、3 期、非劣效性试验(Stockholm III)中,所有经活检证实为直肠腺癌、无不可切除或远处转移迹象、无严重心血管合并症且计划在 18 家瑞典医院进行腹部切除术的患者均符合入组条件。参与者按参与中心分层,采用随机区组分组,接受 5×5 Gy 的放射剂量,1 周内进行手术(短程放疗)或 4-8 周后进行手术(短程放疗后延迟)或 25×2 Gy 的放射剂量,4-8 周后进行手术(长程放疗后延迟)。在方案修订后,随机化可以包括所有三种治疗方法,也可以根据每家医院的偏好仅包括两种短程放疗方法。主要终点是从随机分组日期到局部复发日期的局部复发时间,用危险比(HR)的双侧 90%置信区间上限来评估治疗组之间是否具有非劣效性,如果上限不超过 1.7,则认为治疗组之间具有非劣效性。所有终点均按意向治疗进行分析。本研究在 ClinicalTrials.gov 注册,编号为 NCT00904813。

结果

2007 年 10 月 5 日至 2013 年 1 月 31 日期间,共招募了 840 名患者并进行了随机分组;385 名患者接受了三臂随机分组,其中 129 名患者随机分配至短程放疗组,128 名患者随机分配至短程放疗后延迟组,128 名患者随机分配至长程放疗后延迟组;455 名患者接受了两臂随机分组,其中 228 名患者随机分配至短程放疗组,227 名患者随机分配至短程放疗后延迟组。在所有局部复发患者中,短程放疗组的局部复发中位时间为 33.4 个月(范围 18.2-62.2),短程放疗后延迟组为 19.3 个月(8.5-39.5),长程放疗后延迟组为 33.3 个月(范围 17.8-114.3)。整个试验中,局部复发的累积发生率在接受短程放疗的 357 名患者中为 8 例,在接受短程放疗后延迟的 355 名患者中为 10 例,在接受长程放疗后延迟的 128 名患者中为 7 例(与短程放疗相比:短程放疗后延迟 1.44[95%CI 0.41-5.11];长程放疗后延迟 2.24[0.71-7.10];p=0.48;均判定为非劣效)。在接受短程放疗的 357 名患者中,1 名(<1%)患者出现急性放射性诱导毒性,在接受短程放疗后延迟的 355 名患者中,23 名(7%)患者出现急性放射性诱导毒性,在接受长程放疗后延迟的 128 名患者中,6 名(5%)患者出现急性放射性诱导毒性。当分析三臂随机分组时,所有组别的术后并发症发生率相似(短程放疗组 129 名患者中有 65 例[50%];短程放疗后延迟组 128 名患者中有 48 例[38%];长程放疗后延迟组 128 名患者中有 50 例[39%];与短程放疗相比:短程放疗后延迟 0.59[95%CI 0.36-0.97],长程放疗后延迟 0.63[0.38-1.04],p=0.075)。然而,在对两种短程放疗方案的汇总分析中,短程放疗后延迟组的术后并发症风险显著低于短程放疗组(355 名患者中有 144 例[53%],357 名患者中有 188 例[41%];OR 0.61[95%CI 0.45-0.83],p=0.001)。

结论

与短程放疗后立即手术相比,短程放疗后延迟手术可获得相似的肿瘤学结果。长程放疗后延迟与两种短程放疗方案相似,但显著延长了治疗时间。虽然短程放疗后延迟会出现放射诱导毒性,但与短程放疗相比,术后并发症显著减少。基于这些发现,我们建议短程放疗后延迟手术是替代短程放疗后立即手术的有效方法。

资金来源

瑞典研究委员会、瑞典癌症协会、斯德哥尔摩癌症协会以及斯德哥尔摩地区的医学培训和临床研究协议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验